About Abveris
Abveris is a company based in Quincy (United States) founded in 2014 by Garren Hilow was acquired by Twist Bioscience in November 2021. Abveris has raised $1 million across 1 funding round from investors including Twist Bioscience. Abveris operates in a competitive market with competitors including KBI Biopharma, GenScript, Sino Biological, EirGenix and Aldevron, among others.
- Headquarter Quincy, United States
- Founders Garren Hilow
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1 M (USD)
in 1 rounds
-
Latest Funding Round
$1 M (USD), Seed
Oct 11, 2019
- Investors
-
Employee Count
Not available
-
Acquired by
Twist Bioscience
(Nov 25, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Abveris
Unlock access to complete
Funding Insights of Abveris
Abveris has successfully raised a total of $1M through 1 strategic funding round. The most recent funding activity was a Seed round of $1 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Abveris
Abveris has secured backing from 1 investor. Prominent investors backing the company include Twist Bioscience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Synthetic DNA is synthesized via a semiconductor-based platform.
|
Locked | Locked | Locked |
Investor details for Abveris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abveris
Investment portfolio details for Abveris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Abveris
Detailed financials for Abveris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abveris Comparisons
Peer comparison for Abveris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Abveris
Abveris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, GenScript, Sino Biological, EirGenix and Aldevron, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of protein formulation, process & cell line development, and cGMP services
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Biologics development and manufacturing services are offered by EirGenix.
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Developer of therapeutics for microbiome based diseases
|
Detailed competitors of Abveris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abveris
Complete news archive for Abveris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abveris
Abveris was founded in 2014 and raised its 1st funding round 5 years after it was founded.
Abveris is headquartered in Quincy, United States.
Garren Hilow is the current CEO of Abveris. They have also founded this company.
Abveris is a funded company, having raised a total of $1M across 1 funding round to date.
Abveris was founded in 2014 and is based in Quincy, United States, within the biotechnology sector. Transgenic rodents are utilized by the company to generate hybridomas that produce more immunogenic antibodies. Services encompass custom antibody production for therapeutic uses, monoclonal antibody manufacturing, and provision of antibodies as reagents for research applications. Operations focus on enhancing antibody immunogenicity through advanced hybridoma technology.
Abveris's top competitors include KBI Biopharma, Sino Biological and GenScript.
Abveris has 1 investor. Key investors include Twist Bioscience.